Isis Pharmaceuticals starts ISIS-APOARx Phase 1 clinical study for treatment of atherosclerosis

Published on April 3, 2013 at 8:22 AM · No Comments

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 clinical study for ISIS-APOARx, an antisense drug targeting apolipoprotein(a) for the treatment of atherosclerosis. Apolipoprotein(a) contributes to the formation of plaque in arteries through its attachment to an LDL-C particle in a complex termed lipoprotein(a), or Lp(a).  High levels of Lp(a) are associated with an increased risk of atherosclerosis, coronary heart disease, heart attack and stroke. ISIS-APOARx is designed to reduce Lp(a) by inhibiting the production of apolipoprotein(a). Isis plans to develop ISIS-APOARx to treat patients with high Lp(a) levels who are at high risk of experiencing cardiovascular events.

"Lp(a) is an independent risk factor for coronary heart disease. Although Lp(a) can be measured during a routine lipid blood panel, the lack of drugs that effectively lower Lp(a) have made treating patients with high Lp(a) levels difficult. Because elevated Lp(a) is an inherited genetic condition, patients are unable to adequately control their Lp(a) levels through diet or lifestyle changes.  By inhibiting the production of apolipoprotein(a), ISIS-APOARx is designed to reduce the levels of Lp(a), thereby offering a unique and specific approach to treating patients who have high cardiovascular risk due to high Lp(a) levels," said Walter Singleton, M.D., vice president of development and chief medical officer at Isis. "ISIS-APOARx is part of Isis' strategy to create a cardiovascular disease franchise comprised of drugs that target all the key components of cardiovascular disease, including various atherogenic lipids, inflammation and thrombosis."

The Phase 1 study of ISIS-APOARx is a blinded, placebo-controlled, dose-escalation study in approximately 56 healthy volunteers. The study is designed to assess the safety, tolerability and pharmacokinetics of both single and multiple doses of ISIS-APOARx

Source:

Isis Pharmaceuticals Inc.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Study could pave way for preventing brain and cardiac ischemia induced by atherosclerosis